Inexpensive, serotype-independent protocol for native and bioengineered recombinant adeno-associated virus purification
Recombinant adeno-associated virus (AAV) is a valuable and often used gene therapy vector. With increased demand for highly purified virus comes the need for a standardized purification procedure that is applicable across many serotypes and includes bioengineered viruses. Currently cesium chloride banding or affinity chromatography are the predominate forms of purification. These approaches expose the final purified virus to toxic contaminants or are highly capsid dependent and may require significant optimization to isolate purified AAV. These methods may also limit crude viral lysate processing volume resulting in a significant loss of viral titer. To circumvent these issues, we have developed an AAV purification protocol independent of toxic compounds, supernatant volume and capsid moiety. This purification method standardizes virus purification across native serotype and bioengineered mosaic capsids.
1. Blankinship MJ, Gregorevic P, Allen JM, Harper SQ, Harper H, Halbert CL, et al. Efficient transduction of skeletal muscle using vectors based on adeno-associated virus serotype 6. Mol Ther. 2004;10(4):671–8.
2. Wang J, Faust SM, Rabinowitz JE. The next step in gene delivery: Molecular engineering of adeno-associated virus serotypes. J Mol Cell Cardiol. 2016;50(5):793–802.
3. Bish LT, Morine K, Sleeper MM, Sanmiguel J, Wu D, Gao G, et al. Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat. Hum Gene Ther. 2008;19(12):1359–68.
4. Zincarelli C, Soltys S, Rengo G, Rabinowitz JE. Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther. 2008;16(6):1073–80.
5. Palomeque J, Chemaly ER, Colosi P, Wellman J a, Zhou S, Del Monte F, et al. Efficiency of eight different AAV serotypes in transducing rat myocardium in vivo. Gene Ther. 2007;14(13):989–97.
6. Asokan A, Samulski RJ. An Emerging Adeno-Associated Viral Vector Pipeline for Cardiac Gene Therapy. Hum Gene Ther. 2013;24(11):906–13.
7. Wang W, Barnabei MS, Asp ML, Heinis FI, Arden E, Davis J, et al. Noncanonical EF-hand motif strategically delays Ca2+ buffering to enhance cardiac performance. Nat Med. 2013;19(3):305–12.
8. Guo P, Xiao X, El-Gohary Y, Paredes J, Prasadan K, Shiota C, et al. A simplified purification method for AAV variant by polyethylene glycol aqueous two-phase partitioning. Bioengineered. 2013;4(2):103–6.
9. Guo P, El-Gohary Y, Prasadan K, Shiota C, Xiao X, Wiersch J, et al. Rapid and simplified purification of recombinant adeno-associated virus. J Virol Methods. 2012;183(2):139–46.
10. Hajitou A, Rangel R, Trepel M, Soghomonyan S, Gelovani JG, Alauddin MM, et al. Design and construction of targeted AAVP vectors for mammalian cell transduction. Nat Protoc. 2007;2(3):523–31.
11. Miyake K, Miyake N, Yamazaki Y, Shimada T, Hirai Y. Serotype-independent Method of Recombinant Adeno-associated Virus (AAV) Vector Production and Purification. J Nippon Med Sch. 2012;79(6):394–402.
12. Yang L, Jiang J, Drouin LM, Agbandje-Mckenna M, Chen C, Qiao C, et al. A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. Proc Natl Acad Sci U S A. 2009;106(10):3946–51.
13. Griger JC, Soltys SM, Samulski RJ. Production of recombinant adeno-associated virus vectors using suspensio HEK293 cells and continous harvest of vector from the culture media for GMP FlX and FLT1 clinical vector. Mol. Ther. U.S.A 2015;18(10):1-11.